Results 11 to 20 of about 244,635 (318)

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.

New England Journal of Medicine, 2021
BACKGROUND Diffuse large B-cell lymphoma (DLBCL) is typically treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). However, only 60% of patients are cured with R-CHOP.
H. Tilly, F. Morschhauser, L. Sehn, J. Friedberg, M. Trněný, J. Sharman, C. Herbaux, J. Burke, M. Matasar, S. Rai, K. Izutsu, N. Mehta-Shah, L. Obéric, A. Chauchet, W. Jurczak, Yuqin Song, R. Greil, Larysa Mykhalska, J. Bergua-Burgues, M. Cheung, A. Pinto, H. Shin, G. Hapgood, E. Munhoz, P. Abrisqueta, J. Gau, J. Hirata, Yanwen Jiang, M. Yan, Calvin Lee, C. Flowers, G. Salles   +31 more
semanticscholar   +1 more source

Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

New England Journal of Medicine, 2022
BACKGROUND The prognosis for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) is poor. Glofitamab is a bispecific antibody that recruits T cells to tumor cells.
M. Dickinson, C. Carlo-Stella, F. Morschhauser, E. Bachy, P. Corradini, G. Iacoboni, C. Khan, T. Wróbel, F. Offner, M. Trněný, Shang-Ju Wu, G. Cartron, M. Hertzberg, A. Sureda, D. Pérez-Callejo, L. Lundberg, J. Relf, M. Dixon, E. Clark, K. Humphrey, M. Hutchings   +20 more
semanticscholar   +1 more source

A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma

Nature Medicine, 2022
Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) have both demonstrated impressive clinical activity in relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL).
E. Bachy, S. le Gouill, Roberta Di Blasi, P. Sesques, G. Manson, G. Cartron, D. Beauvais, L. Roulin, F. Gros, M. Rubio, P. Bories, J. Bay, C. C. Llorente, S. Choquet, R. Casasnovas, M. Mohty, S. Guidez, M. Joris, M. Loschi, S. Carras, J. Abraham, A. Chauchet, Laurianne Drieu La Rochelle, B. Deau-Fischer, O. Hermine, T. Gastinne, J. Tudesq, E. Gat, F. Broussais, C. Thieblemont, R. Houot, F. Morschhauser   +31 more
semanticscholar   +1 more source

Intravascular diffuse large B-cell lymphoma with acquired ichthyosis: A case report

SAGE Open Medical Case Reports, 2023
Intravascular diffuse large B-cell lymphoma is an exceedingly rare subtype of B-cell lymphomas. This cancer is often associated with poor prognosis and can be lethal if left untreated.
Zainab Ridha, Hanieh Zargham, May Chergui, Elena Netchiporouk   +3 more
doaj   +1 more source

Epidemiology and etiology of diffuse large B-cell lymphoma.

Seminars in hematology (Print), 2023
As the most common non-Hodgkin lymphoma subtype, diffuse large B-cell lymphoma (DLBCL) incidence patterns generally parallel that for NHL overall. Globally, DLBCL accounts for a third of all NHLs, ranging between 20% and 50% by country.
Sophia S. Wang
semanticscholar   +1 more source

A Phase I/II first-line study of R-CHOP plus B-cell receptor/NF-κB-double-targeting to molecularly assess therapy response [PDF]

, 2019
The ImbruVeRCHOP trial is an investigator-initiated, multicenter, single-arm, open label Phase I/II study for patients 61-80 years of age with newly diagnosed CD20+ diffuse large B-cell lymphoma and a higher risk profile (International Prognostic Index ...
Anagnostopoulos, Ioannis, Bittner, Aitomi, Denker, Sophy, Frick, Mareike, Hummel, Michael, Kase, Julia, Na, Il-Kang, Schmitt, Clemens A.   +7 more
core   +2 more sources

Primary gastrointestinal diffuse large B-cell lymphoma: A prospective study from South India

South Asian Journal of Cancer, 2019
Background: Gastrointestinal tract (GIT) is the most common extranodal site for non-Hodgkin's lymphoma (NHL) and constitutes about 10%-15% of all NHL. This was a prospective study to evaluate the epidemiological, clinicopathological characteristics, and ...
Babu Suresh, Vikas Asati, K C Lakshmaiah, Govind Babu, D Lokanatha, Linu Abraham Jacob, K N Lokesh, A H Rudresh, L K Rajeev, Saldanha Smitha, Abhishek Anand, Rajesh Patidar, C S Premalata   +12 more
doaj   +1 more source

Primary mediastinal lymphoma: diagnosis and treatment options. [PDF]

, 2014
Primary mediastinal large B-cell lymphoma (PMBCL) is a unique B-cell lymphoma variant that arises from a putative thymic medulla B cell. It constitutes 2-4% of non-Hodgkin lymphomas and occurs most frequently in young females. PMBCL is characterized by a
DI ROCCO, Alice, Foa, Roberto, Martelli, Maurizio, Perrone, Salvatore, Russo, E   +4 more
core   +1 more source

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B‐Cell Lymphoma

New England Journal of Medicine, 2019
BACKGROUND Patients with diffuse large B‐cell lymphoma that is refractory to primary and second‐line therapies or that has relapsed after stem‐cell transplantation have a poor prognosis. The chimeric antigen receptor (CAR) T‐cell therapy tisagenlecleucel
S. Schuster, M. Bishop, C. Tam, E. Waller, P. Borchmann, J. Mcguirk, U. Jäger, S. Jaglowski, C. Andreadis, J. Westin, I. Fleury, V. Bachanova, R. Foley, Joy P. Ho, S. Mielke, J. Magenau, H. Holte, Serafino Pantano, L. Pacaud, R. Awasthi, J. Chu, Ö. Anak, G. Salles, R. Maziarz   +23 more
semanticscholar   +1 more source

Low levels of monoclonal small B cells in the bone marrow of patients with diffuse large B-cell lymphoma of activated B-cell type but not of germinal center B-cell type

Haematologica, 2010
Background Multiparameter flow cytometry allows the detection of minor monoclonal B-cell populations. Using this technique combined with morphology, we were struck by the presence of minor populations of small monoclonal B cells in bone marrows of ...
Anne M. Tierens, Harald Holte, Abdirashid Warsame, Ida M. Ikonomou, Junbai Wang, Wing C. Chan, Jan Delabie   +6 more
doaj   +1 more source